Insys Therapeutics Inc (NASDAQ:INSY) – Jefferies Financial Group decreased their FY2018 earnings per share (EPS) estimates for Insys Therapeutics in a report released on Wednesday, November 7th. Jefferies Financial Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will earn ($1.32) per share for the year, down from their previous forecast of ($1.24). Jefferies Financial Group currently has a “Buy” rating and a $10.00 target price on the stock. Jefferies Financial Group also issued estimates for Insys Therapeutics’ Q4 2018 earnings at ($0.33) EPS, FY2019 earnings at ($1.07) EPS, FY2020 earnings at ($0.66) EPS, FY2021 earnings at ($0.24) EPS and FY2022 earnings at $0.31 EPS.
Several other equities research analysts have also commented on INSY. ValuEngine upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research downgraded shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Piper Jaffray Companies set a $4.00 target price on shares of Insys Therapeutics and gave the company a “sell” rating in a research report on Saturday, August 11th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Insys Therapeutics in a report on Thursday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.67.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.30 million for the quarter, compared to the consensus estimate of $24.05 million. Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 200.14%. The business’s revenue was down 40.4% compared to the same quarter last year. During the same period last year, the company posted ($2.30) EPS.
Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in Insys Therapeutics during the second quarter worth about $131,000. Creative Planning bought a new stake in Insys Therapeutics during the third quarter worth about $153,000. JPMorgan Chase & Co. boosted its stake in Insys Therapeutics by 303.5% during the first quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock worth $155,000 after acquiring an additional 19,273 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Insys Therapeutics by 47.4% during the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after acquiring an additional 10,001 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Insys Therapeutics by 35.3% during the third quarter. Wells Fargo & Company MN now owns 77,101 shares of the specialty pharmaceutical company’s stock worth $778,000 after acquiring an additional 20,100 shares in the last quarter. 18.04% of the stock is currently owned by institutional investors and hedge funds.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
See Also: Put Option
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.